Previous close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 1.50 |
Expiry date | 2024-08-16 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | 141 |
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the presentation of updated exploratory subgroup analyses from the SIENDO study (NCT03555422), in patients with advanced or recurrent TP53 wild-type endometrial cancer at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The data were presented in a special ASCO plenary series rapid abstract update session on June 1 at 12:30pm CT and simult
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Global Healthcare Conference in a fireside chat on Wednesday, June 5, 2024 at 1:00 p.m. ET in New York, NY.
Karyopharm Therapeutics ( NASDAQ:KPTI ) First Quarter 2024 Results Key Financial Results Revenue: US$33.1m (down 14...